Thursday, June 19th, 2025
Stock Profile: KYMR

Kymera Therapeutics, Inc. (KYMR)

Market: NASD | Currency: USD

Address: 200 Arsenal Yards Boulevard

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, Show more




📈 Kymera Therapeutics, Inc. Historical Chart






📊 Statistics





💰 Dividend History


No dividend history available.



📅 Earnings & EPS History for Kymera Therapeutics, Inc.


DateReported EPS
2026-05-07 (estimated upcoming)-
2026-02-25 (estimated upcoming)-
2025-10-29 (estimated upcoming)-
2025-10-28 (estimated upcoming)-
2025-08-05 (estimated upcoming)-
2025-08-04 (estimated upcoming)-
2025-05-09-
2025-05-09-0.82
2025-04-30-
2025-04-29-
2025-02-27-0.88
2024-10-31-0.82
2024-08-07-0.58
2024-08-06-0.58
2024-05-02-0.62
2024-05-01-0.62
2024-02-22-0.25
2024-02-21-0.25
2023-11-02-0.9
2023-11-01-0.9
2023-08-03-0.67
2023-08-02-0.67
2023-05-04-0.7
2023-05-03-0.7
2023-02-23-0.6
2023-02-22-0.6
2022-11-03-0.79
2022-11-02-0.79
2022-08-09-0.78
2022-08-08-0.78
2022-05-03-0.71
2022-05-02-0.71
2022-02-24-0.66
2022-02-23-0.66
2021-11-10-0.56
2021-11-09-0.56
2021-08-06-0.55
2021-08-05-0.55
2021-05-06-0.29
2021-05-05-0.29
2021-03-11-0.29
2021-03-10-0.29
2020-11-05-0.39
2020-11-04-0.39
2020-08-21-
2020-08-20-




📰 Related News & Research


No related articles found for "kymera therapeutics".